invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces that two abstracts on its clinical stage lead program, APN401, have been accepted for poster presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2022) being held in Boston, MA, on November 8-12, 2022.
The posters will present new data from the ongoing Phase 1b clinical trial of APN401, a candidate treatment from invIOs’s EPiC cell therapy platform targeting the master checkpoint inhibitor Cbl-b.
Dr. Romana Gugenberger, CMSO, and Dr. Alexander Dohnal, Head of R&D, will attend SITC 2022 and are available for meetings during the event.
Details of the invIOs SITC 2022 poster presentations
Title: “APN401, a novel EPiC-based anti-cancer cell therapy, case report: Cbl-b silenced, autologous PBMCs induced stable disease in an appendix carcinoma patient” (abstract #653)
Title: “Cbl-b silenced, autologous peripheral blood mononuclear cells as a novel anti-cancer therapy using the closed cell processing platform EPiC – a phase 1b trial with APN401” (abstract #722)
The Posters will be on display in the Poster Hall located in Hall C of the Boston Convention & Exhibition Center. The Poster Hall will be open from 9 a.m. to 9 p.m. on Thursday, November 10, 2022, and from 9 a.m. to 8:30 p.m. on Friday, November 11, 2022.
The ePosters will also be available to attendees on the SITC 2022’s Virtual ePoster Hall, as well as on the SITC meeting app and the SITC virtual meeting platform. invIOs will also make the ePosters available on its website.
Abstracts for the posters will be published on Monday, November 7, 2022, in a supplement of the Journal for ImmunoTherapy of Cancer (JITC) and made available on the SITC website.
